Timothy D. McHugh

7 ta ish

University College London

1. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis

   Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis +15

   MaqolaOAOchiq kirishTuberculosis Research and EpidemiologyNew England Journal of Medicine20228 iqtibos

   ABIABI:AkademIndex/2022.article.000002

2. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis

   Francesca Conradie, Andreas H. Diacon, Nosipho Ngubane +15

   MaqolaOAOchiq kirish20207 iqtibos

   ABIABI:AkademIndex/2026.other.006850

3. Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis

   Francesca Conradie, Tatevik R. Bagdasaryan, Borisov Se +25

   MaqolaOAOchiq kirish20227 iqtibos

   ABIABI:AkademIndex/2026.other.006859

4. Global Tuberculosis Report 2020 – Reflections on the Global TB burden, treatment and prevention efforts

   Jeremiah Chakaya, Mishal Khan, Francine Ntoumi +14

   Maqola20213 iqtibos

   ABIABI:AkademIndex/2026.other.594397

5. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis

   Catherine Berry, Philipp du Cros, Katherine Fielding +7

   MaqolaOAOchiq kirish20222 iqtibos

   ABIABI:AkademIndex/2026.other.133232

6. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

   Simon Tiberi, Nelita du Plessis, Gerhard Walzl +11

   Sharh maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.360228

7. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China

   David S.C. Hui, Esam I. Azhar, Tariq A. Madani +9

   Tahririyat maqolasi20202 iqtibos

   ABIABI:AkademIndex/2026.other.392219